47.33

2.79% -1.36

After Hours: 47.33

Kymera Therapeutics Inc (KYMR)

Overview News Price History Option Chain Financials Discussions Forecast

Kymera Therapeutics Inc stock is traded at $47.33, with a volume of 554.98K. It is down -2.79% in the last 24 hours and down -2.13% over the past month. Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Previous Close:

$48.69

Open:

$48.38

24h Volume:

554.98K

Relative Volume:

1.02

Market Cap:

$3.04B

Revenue:

$88.55M

Net Income/Loss:

$-157.85M

P/E Ratio:

-17.15

EPS:

-2.76

Net Cash Flow:

$-137.92M

1W Performance:

-5.30%

1M Performance:

-2.13%

6M Performance:

+17.74%

1Y Performance:

+240.50%

1-Day Range:

$46.78

$49.66

1-Week Range:

$46.78

$53.27

52-Week Range:

$9.60

$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name

Kymera Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

857-285-5314

Address

500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN

Employee

181

Twitter

Next Earnings Date

2024-08-07

Latest SEC Filings

KYMR's Discussions on Twitter

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-30-23	Initiated	Truist	Buy
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy
Aug-03-22	Initiated	Goldman	Buy
Jul-20-22	Initiated	SVB Leerink	Mkt Perform
Apr-28-22	Initiated	Credit Suisse	Outperform
Mar-10-22	Initiated	JP Morgan	Neutral
Feb-10-22	Initiated	Wells Fargo	Overweight
Sep-30-21	Initiated	B. Riley Securities	Neutral
Sep-30-21	Initiated	Stifel	Buy
Sep-10-21	Downgrade	BofA Securities	Buy → Neutral
May-21-21	Initiated	UBS	Buy
Apr-14-21	Initiated	Berenberg	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Sep-15-20	Initiated	BofA Securities	Neutral
Sep-15-20	Initiated	Cowen	Outperform
Sep-15-20	Initiated	Guggenheim	Buy
Sep-15-20	Initiated	Morgan Stanley	Equal-Weight

View All

Kymera Therapeutics Inc Stock (KYMR) Latest News

06:20 AM

XTX Topco Ltd Acquires Shares of 6,748 Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

06:20 AM

05:34 AM

Driehaus Capital Management LLC Invests $6.67 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

05:34 AM

12:00 PM

Renaissance Technologies LLC Purchases Shares of 143,093 Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

12:00 PM

Sep 29, 2024

Susquehanna Portfolio Strategies LLC Sells 3,700 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Sep 29, 2024

Renaissance Technologies LLC Purchases Shares of 143,093 Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Sep 29, 2024

Sep 27, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Profund Advisors LLC - MarketBeat

Sep 26, 2024

Sep 25, 2024

Kymera Therapeutics (NASDAQ:KYMR) Reaches New 52-Week High at $53.00 - MarketBeat

Sep 25, 2024

Kymera's KT-621 shows promise in preclinical studies - Investing.com

Sep 25, 2024

Kymera's KT-621 shows promise in preclinical studies By Investing.com - Investing.com UK

Sep 25, 2024

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 - EIN News

Sep 25, 2024

Sep 24, 2024